Table 1 Enriched pathways in the parental and antibody-treated cell lines
From: Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
| Â | ES | FDR q-val |
|---|---|---|
GSEA pathway (parental cell line, n = 2) |  |  |
 HALLMARK_PANCREAS_BETA_CELLS | 0.83 | 0.274 |
 HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY | 0.6 | 0.274 |
 HALLMARK_COAGULATION | 0.52 | 1.000 |
 HALLMARK_PEROXISOME | 0.51 | 0.995 |
 HALLMARK_MYC_TARGETS_V2 | 0.44 | 0.926 |
 HALLMARK_GLYCOLYSIS | 0.42 | 0.722 |
GSEA pathway (anti-S100A11 antibody-treated cell line, n = 2) |  |  |
 HALLMARK_PI3K_AKT_MTOR_SIGNALING | −0.56 | 0.819 |
 HALLMARK_PROTEIN_SECRETION | −0.47 | 0.47 |
 HALLMARK_KRAS_SIGNALING_DN | −0.47 | 0.811 |
 HALLMARK_MYOGENESIS | −0.47 | 0.87 |
 HALLMARK_MITOTIC_SPINDLE | −0.33 | 0.887 |
 HALLMARK_P53_PATHWAY | −0.35 | 0.409 |
